- AU$92.05bn
- AU$107.79bn
- $15.80bn
Australia's CSL on track for worst week in 8 months on forecast cut, impairments
Citi turns neutral on Australia's CSL on growth uncertainty, execution risks
Brief: PAHO Signs Agreement To Reserve Pandemic Influenza Vaccine Supply For LatAm & Caribbean
Australian health stocks extend decline in CSL-led rout
CSL slips 6% as Citi slashes target price, Morningstar urges firm to hire new CEO
Morningstar trims outlook for Australia's CSL, urges firm to hire new CEO
Australian shares fall after Trump rebuffs Iran; CSL sinks to near decade‑low
CSL slips to over 9-year low on annual forecast downgrade, potential $5 billion impairments
Australia's CSL tanks on trimming annual forecasts, flagging $5 billion impairments
Australia’s CSL cuts 2026 profit and revenue outlook, flags impairments (updated)
Brief: CSL Expects FY26 Revenue $15.2 Bln, NPATA $3.1 Bln At Constant Currency
Australia's CSL cuts 2026 earnings forecast as payoff from growth initiatives delayed
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Australia's CSL falls to over 8-yr low as Pentagon ends flu vaccine mandate
Australian healthcare stocks hit 8-year low as CSL extends vaccine rout
Australia's CSL hits 9-year low after US scraps mandatory flu vaccines for military
Australia's CSL knocked by Pentagon flu policy shift, stock sinks to 2017 low
Australian superannuation fund HESTA names ESSSuper chief Robbie Campo as next CEO
Jefferies trims CSL's PT as growth in key markets falls short of 'stellar'